Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 6, 2023; 11(16): 3813-3821
Published online Jun 6, 2023. doi: 10.12998/wjcc.v11.i16.3813
Blood typing and transfusion therapy in a patient with A2 subtype acute myeloid leukemia M2: A case report
Xiao-Chuan Kuang, Shi-Hua Zhang, Yi-Jing Cen, Jian-Bo Zhang, Yu-Song Liu
Xiao-Chuan Kuang, Yi-Jing Cen, Jian-Bo Zhang, Yu-Song Liu, Department of Clinical Laboratory, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Chengdu 610000, Sichuan Province, China
Shi-Hua Zhang, Department of Gastroenterology, Pidu District People's Hospital, Chengdu 610000, Sichuan Province, China
Author contributions: Kuang XC and Zhang SH designed research; Liu YS performed research; Zhang JB and Liu YS contributed new reagents or analytic tools; Cen YJ analyzed data; Kuang XC and Zhang SH wrote the paper; Kuang XC and Zhang SH have contributed equally to the study.
Informed consent statement: This work has been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association. This study was approved by the Ethics Committee, Hematology Department, Sichuan Provincial People's Hospital [Lun Sheng (Research Institute) No. 549, 2021], and all participants provided written informed consent.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu-Song Liu, BSc, Doctor, Department of Clinical Laboratory, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, No. 18 Huanhua North Road, Chengdu 610000, Sichuan Province, China. 18980532562@163.com
Received: October 10, 2022
Peer-review started: October 10, 2022
First decision: January 12, 2023
Revised: February 25, 2023
Accepted: April 20, 2023
Article in press: April 20, 2023
Published online: June 6, 2023
Core Tip

Core Tip: There has always been a debate on the large-scale transfusion therapy for acute myeloid leukemia (AML). This study provides strong and favorable evidence for the clinical treatment of blood transfusion. There are few specific reports in the literature on the treatment of blood transfusion for patients with AML-M2 blood type A2, and this study provides a protocol and precedent for the treatment of blood transfusion for patients with rare subtype AML. The study can provide clinical reference data for supporting transfusion therapy in patients with clinically rare blood type leukemia.